Roivant Sciences
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that incubates, develops, and commercializes innovative medicines and healthcare technologies across diverse therapeutic areas. The company operates through a unique "Vant" model, founding nimble subsidiary companies focused on specific drug candidates, biological targets, and medical technologies in immunology, dermatology, and oncology. Its primary revenue drivers stem from commercial sales of approved pharmaceutical treatments, strategic out-licensing agreements, upfront milestone payments, and biopharmaceutical transaction proceeds. Roivant holds a prominent position in the biopharmaceutical industry as a pioneer in decentralized drug development, rapidly advancing late-stage clinical assets to regulatory approval. The enterprise focuses on executing global clinical trials, acquiring promising drug candidates from larger pharmaceutical firms, expanding its immunology pipeline, and developing targeted biological therapies. Roivant Sciences Ltd. maintains principal executive offices in New York, United States, and Basel, Switzerland, with its common stock publicly listed on the Nasdaq Global Select Market.
30 of the funds FundTelligence covers report a position in Roivant Sciences.
- Legal name
- Roivant Sciences Ltd
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 30
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Roivant Sciences
- Morgan Stanley Global Insight — Morgan Stanley · 7.68 % (largest positions only, September 2026)
- Morgan Stanley US Advantage Fund — Morgan Stanley · 4.56 % (largest positions only, September 2026)
- Morgan Stanley US Growth Fund — Morgan Stanley · 4.55 % (largest positions only, September 2026)
- UBS Biotech Equity Fund — UBS · 4.2 % (largest positions only, September 2026)
- DNB Fund Women's Health — DNB · 3.21 % (full portfolio disclosed, August 2026)
- Polar Capital Biotechnology Fund — Polar Capital · 3.1 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 2.9 % (full portfolio disclosed, September 2026)
- Eika Global — Eika · 1.86 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 30 funds holding it.